Anondita Medicare Ltd

Anondita Medicare Ltd

₹ 1,103 3.46%
22 May - close price
About

Founded in March 2024, Anondita Medicare Limited manufactures flavored male condoms, with its flagship product branded as “COBRA.”[1]

Key Points

Business Profile:[1]
Anondita Medicare manufactures male (and recently, female) condoms, flagship brand “COBRA,” with in-house printing/packaging and 100% electronic testing.

  • Market Cap 1,995 Cr.
  • Current Price 1,103
  • High / Low 1,227 / 262
  • Stock P/E 59.6
  • Book Value 71.5
  • Dividend Yield 0.00 %
  • ROCE 43.6 %
  • ROE 40.0 %
  • Face Value 10.0

Pros

Cons

  • Stock is trading at 15.4 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2024 Mar 2025 Sep 2025 Mar 2026
31 46 54 83
22 30 35 52
Operating Profit 10 16 19 31
OPM % 31% 35% 35% 38%
0 0 0 0
Interest 1 1 2 2
Depreciation 0 0 0 1
Profit before tax 8 14 17 30
Tax % 25% 26% 25% 28%
6 10 13 21
EPS in Rs 4.29 7.67 7.11 10.47
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
77 137
51 87
Operating Profit 26 51
OPM % 33% 37%
0 1
Interest 3 4
Depreciation 1 1
Profit before tax 22 47
Tax % 25% 27%
16 34
EPS in Rs 11.88 18.49
Dividend Payout % 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 78%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 112%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 40%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
Equity Capital 13 18
Reserves 25 111
27 34
13 22
Total Liabilities 78 185
14 84
CWIP 6 0
Investments 3 0
55 101
Total Assets 78 185

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
-10 11
-23 -63
33 61
Net Cash Flow -0 9
Free Cash Flow -30 -52
CFO/OP -38% 28%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
Debtor Days 127 138
Inventory Days 141 126
Days Payable 40 49
Cash Conversion Cycle 228 215
Working Capital Days 129 163
ROCE % 44%

Insights

In beta
Jan 2026 Mar 2027 (P)
Installed Manufacturing Capacity
million pieces per annum ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Capacity Under Trial Production
million pieces per annum ・Standalone data
Existing Capacity Utilization
million pieces per annum ・Standalone data
Existing Capacity Utilization (%)
% ・Standalone data
IPO Proceeds Re-allocation to Working Capital
INR Lakhs ・Standalone data
IPO Proceeds Utilized (Total)
INR Lakhs ・Standalone data
IPO Unutilized Amount
INR Lakhs ・Standalone data
L1 GeM Tender Supply Volume (Condoms)
pieces ・Standalone data
L1 GeM Tender Supply Volume (Family Planning Items)
pieces ・Standalone data
Order Value (CMSS GeM Tender)
INR ・Standalone data
Projected Turnover for FY2025-26
INR Crores ・Standalone data
Target Capacity Expansion (Noida Facility)
million pieces per annum ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

5 Recently
Sep 2025Mar 2026
61.79% 62.40%
4.24% 3.40%
6.55% 5.70%
27.42% 28.50%
No. of Shareholders 621530

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents